Following a positive readout for its closely watched PD-1xVEGF bispecific ivonescimab, Akeso has won the FDA’s go-ahead for ...

Interim results from a study in China suggest ivonescimab may reduce the risk of death versus Keytruda, but the difference ...

Pfizer has linked its PD-1 inhibitor to a 32% reduction in the risk of disease-related events in a phase 3 bladder cancer ...

Penpulimab has picked up a pair of approvals in nasopharyngeal carcinoma (NPC), becoming only the second drug to be cleared ...

The global checkpoint inhibitor refractory cancer market is experiencing significant growth, with an expected valuation of USD 38.69 billion in 2023. This expansion is fueled by the rising health ...

Pfizer’s sasanlimab, when used with standard of care, reduced the likelihood of disease recurrence or progression, death due ...

The FDA approved the PD-1 inhibitor penpulimab, with two indications, for treating non-keratinizing nasopharyngeal carcinoma ...

"Alternatively, regulators could limit market access to a patient group that ... in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538). Abstract CRA9006, ASCO 2013.

An ivonescimab-chemotherapy combination succeeded in a study in China. Elsewhere, the FDA asked Novavax for more COVID ...

Explore the evolving landscape of non-small cell lung cancer (NSCLC) treatment, where targeted therapies address ten actionable genomic alterations (AGAs). Discover innovations in EGFR mutations, ...

This could differentiate ivonescimab as there is potentially higher expression (presence) of both PD-1 and VEGF in tumor ... are listed on the Nasdaq Global Market (symbol "SMMT").